10x Genomics (TXG) Non-Current Debt (2018 - 2019)
10x Genomics (TXG) reported Non-Current Debt of $19.8 million for Q4 2019, down 22.17% on a YoY basis from $25.5 million in Q4 2018, and down 11.07% sequentially from $22.3 million in Q3 2019.
10x Genomics (TXG) Non-Current Debt (2018 - 2019) Analysis & Trends
10x Genomics (TXG) has 2 years of Non-Current Debt data on file, last reported at $19.8 million in Q4 2019.
- For the quarter ending Q4 2019, Non-Current Debt fell 22.17% year-over-year to $19.8 million; the trailing twelve-month figure through Dec 2019 stood at $19.8 million (down 22.17% YoY), and the FY2019 full-year result was $19.8 million, down 22.17% from the prior year.
- Non-Current Debt slipped to $19.8 million in Q4 2019, from $22.3 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $25.5 million in Q4 2018 to a low of $19.8 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 29.34 Bn | 22.03 Bn | 662.02 Mn | - |
| 2 | BrightSpring Health Services | 13.49 Bn | 12.59 Bn | 482.22 Mn | 2.44 Bn |
| 3 | Healthequity | 7.96 Bn | 7.70 Bn | 256.31 Mn | 942.66 Mn |
| 4 | 10x Genomics | 6.17 Bn | 5.63 Bn | 106.18 Mn | - |
| 5 | Hinge Health | 6.02 Bn | 5.70 Bn | 154.23 Mn | - |
| 6 | MiniMed | 4.19 Bn | 3.89 Bn | 480.00 Mn | - |
| 7 | Waystar Holding | 4.14 Bn | 4.07 Bn | 216.84 Mn | 1.46 Bn |
| 8 | Doximity | 3.82 Bn | 3.08 Bn | 125.97 Mn | - |
| 9 | Privia Health | 3.10 Bn | 2.73 Bn | - | - |
| 10 | Omnicell | 1.81 Bn | 1.57 Bn | 140.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 19.84 Mn |
| Sep 30, 2019 | 22.31 Mn |
| Dec 31, 2018 | 25.49 Mn |